A pair of drugmakers priced their initial public offerings on Thursday, delivering the best month for US health care ...

Capital Breakfast's Jordan North, Chris Stark & Sian Welby paid a visit to the haunted London Tombs to try out their ...

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

A hunt for mountain lions along the Gila River in New Mexico led the hunter, Charles Elliott, and his guide on a chase ...

Drug developer Maze Therapeutics said on Monday it was targeting a valuation of up to $728.1 million in its New York initial ...

Catch The Office, The Traitors, Twisted Metal, NFL, Premier League, college hoops, WWE premium live events, and blockbuster ...

Seven years ago, researchers caught an unexpected phenomenon on film: A pool of red dye that somehow 'knew' how to solve a maze filled with milk. Propelled forward by a couple drops of soap, it ...

Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a ...

Maze Therapeutics became the latest drug developer to list in New York on Friday, with its shares rising nearly 1% in their debut, giving the company a valuation of $690.37 million.

Chapter 4 is as much a puzzle game as it is a story-focused horror experience. This part of the game puts the onus on the ...

Obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics have met their IPO expectations as the two companies prepare to join the Nasdaq this morning. | Obesity biotech Metsera and ...

After building a loyal PC following, Krafton’s take on Dark and Darker Mobile earns a rightful spot alongside the finest mobile RPGs.